Andere Kunden interessierten sich auch für
![The Essential Guide to Lithium Treatment]( "The Essential Guide to Lithium Treatment")
The Essential Guide to Lithium Treatment48,99 €![Neuropsychopharmacology]( "Neuropsychopharmacology")
Neuropsychopharmacology83,99 €![Biomarkers for Alzheimer¿s Disease Drug Development]( "Biomarkers for Alzheimer¿s Disease Drug Development")
Biomarkers for Alzheimer¿s Disease Drug Development81,99 €![The Neuropharmacology of Alcohol]( "The Neuropharmacology of Alcohol")
The Neuropharmacology of Alcohol162,99 €![The Pharmacist Guide to Implementing Pharmaceutical Care]( "The Pharmacist Guide to Implementing Pharmaceutical Care")
The Pharmacist Guide to Implementing Pharmaceutical Care111,99 €![Biologics to Treat Substance Use Disorders]( "Biologics to Treat Substance Use Disorders")
Biologics to Treat Substance Use Disorders95,99 €![Ketamine for Treatment-Resistant Depression]( "Ketamine for Treatment-Resistant Depression")
Ketamine for Treatment-Resistant Depression81,99 €
In this book, the four leading experts on the ACE inhibitors donepezil, galantamine, and rivastigmine and the NMDA receptor antagonist memantine explain the practical pharmacology of these symptomatic drugs with the aim of providing a sound basis for their clinical use in patients with Alzheimer's disease. In addition, an introductory chapter considers the basic theory of pharmacology for Alzheimer's disease and the book closes with an overview of the ways in which symptomatic drugs for dementia are used.
The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer's disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. The failure of clinical trials of these drugs to yield satisfactory results has, however, meant that for the time being patients continue to be treated only with symptomatic drugs. There is accordingly a need to become more proficient in the use of symptomatic medicines, and it is against the background of this quest that Practical Pharmacology for Alzheimer's Disease will be of wide interest.
The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer's disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. The failure of clinical trials of these drugs to yield satisfactory results has, however, meant that for the time being patients continue to be treated only with symptomatic drugs. There is accordingly a need to become more proficient in the use of symptomatic medicines, and it is against the background of this quest that Practical Pharmacology for Alzheimer's Disease will be of wide interest.
"Written by four experts in dementia research, this book describes the pharmacology of the four symptomatic drugs used in the treatment of Alzheimer's disease. It provides an overview of the basic theories of the pharmacology of Alzheimer's disease and the way in which the medications are used for the treatment of dementia. ... book is most suitable for geriatric psychiatrists, geriatric medicine specialists, and neurologists who spend a significant amount of time treating people with Alzheimer's disease and other dementias." (Danielle L. Anderson, Doody's Book Reviews, June, 2016)